KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$310.84
+1.90%Nov 2, 2026, 18:43 UTC
Krystal Biotech, Inc. shares traded lower on Monday.
Source:Nov 2, 2026, 17:20 UTC
Krystal Biotech reported quarterly earnings of $2.05 per share, above the Zacks Investment Research, Inc. consensus estimate of $1.84 and compared with $2.66 per share a year earlier.
Source:Nov 2, 2026, 12:00 UTC
Krystal Biotech, Inc. announced that VYJUVEK pricing negotiations in Germany and Italy had been completed.
Source:Nov 2, 2026, 12:00 UTC
Krystal Biotech, Inc. reported $127.3 million in global VYJUVEK revenue for the third quarter of 2026 and $1.1 billion in cumulative revenue since launch.
Source:Nov 2, 2026, 12:00 UTC
Krystal Biotech, Inc.'s board authorized a share repurchase program of up to $400 million.
Source:Oct 15, 2026, 11:00 UTC
Krystal Biotech announced positive clinical data for KB113 in three patients with Gorlin syndrome, reporting regression in over 80% of assessed basal cell carcinoma lesions and histologically confirmed clearance of an injected lesion in each patient.
Aug 3, 2026, 11:00 UTC
Krystal Biotech reported financial results for the second quarter ended June 30, 2026, with $119.2 million in global VYJUVEK revenue and $1.1 billion in cash and investments.